Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Blood Research|December 26, 2025
Prognostic impact of lymphocyte to monocyte ratio in patients with myelodysplastic neoplasms/syndromesWan-Hsuan Lee, Chien-Chin Lin, Xavier Cheng-Hong Tsai, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 30, 2025
Molecular Milestones and Survival Outcomes of Ponatinib Treatment in Patients With Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: A Real-World AnalysisTai-Chung Tseng, Yu-Sung Chang, Xavier Cheng-Hong Tsai, et al.
Blood Cancer Journal|September 8, 2018
GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemiaFeng-Ming Tien, Hsin-An Hou, Cheng-Hong Tsai, et al.
American Journal of Hematology|March 2, 2023
Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemiaMin-Yen Lo, Xavier Cheng-Hong Tsai, Chien-Chin Lin, et al.
Blood Cancer Journal|May 19, 2025
Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutationsSao-Chih Ni, Chi-Yuan Yao, Xavier Cheng-Hong Tsai, et al.
Blood Advances|December 18, 2024
Acute Promyelocytic Leukemia Asian Consortium study of arsenic trioxide in newly diagnosed patients: impact and outcomeHarinder Gill, Radha Raghupathy, Hsin-An Hou, et al.
Blood Cancer Journal|January 22, 2024
Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutationsFeng-Ming Tien, Chi-Yuan Yao, Xavier Cheng-Hong Tsai, et al.
Oncotarget|January 27, 2016
Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemiaHsin-An Hou, Chieh-Yu Liu, Yuan-Yeh Kuo, et al.
Bone Marrow Transplantation|October 21, 2021
Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remissionFeng-Ming Tien, Cheng-Hong Tsai, Sheng-Chuan Huang, et al.
Blood|January 10, 2023
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trialYuqin Song, Hervé Tilly, Shinya Rai, et al.
Pageof 7